| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-5322-5MG | Tepotinib | 5mg | $126.00 | |
| GBM-5322-25MG | Tepotinib | 25mg | $420.00 |
| Bioassays Specification | |
| Bio-Activity | c-MET inhibitor |
| Chemical Name | 3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile |
| Function / Pharmacology | Selective type 1b MET inhibitor. In biochemical assays using His6-tagged recombinant human MET kinase domain, tepotinib inhibited kinase activity in a concentration-dependent manner with IC50=1.8 nM1. It displays marked antitumor activity in MET-dependent tumor models2. It crosses the blood-brain barrier and displays intracranial antitumor activity3. Teptotinib can overcome EGFR inhibitor resistance mediated by aberrant c-Met activation4 and is in clinical use for non-small cell lung cancer harboring MET exon 14 skipping alterations. |
| CAS# | 1100598-32-0 |
| MW | 492.6 |
| Molecular Formula | C29H28N6O2 |
| Solubility | Soluble in Water (17 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1. J Albers et al. Mol. Cancer Ther. 2023 22:833 2. F Bladt et al. Clin. Cancer Res. 2013 19:2941 3. M Friese-Hamim et al. Lung Cancer 2022 163:77 4. M Friese-Hamim et al. Am. J. Cancer Res. 2017 7:962 |
| Antibody Specification | |
| Alternate Names | EMD-1214063 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | c-MET inhibitor |
| Chemical Name | 3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile |
| Function / Pharmacology | Selective type 1b MET inhibitor. In biochemical assays using His6-tagged recombinant human MET kinase domain, tepotinib inhibited kinase activity in a concentration-dependent manner with IC50=1.8 nM1. It displays marked antitumor activity in MET-dependent tumor models2. It crosses the blood-brain barrier and displays intracranial antitumor activity3. Teptotinib can overcome EGFR inhibitor resistance mediated by aberrant c-Met activation4 and is in clinical use for non-small cell lung cancer harboring MET exon 14 skipping alterations. |
| CAS# | 1100598-32-0 |
| MW | 492.6 |
| Molecular Formula | C29H28N6O2 |
| Solubility | Soluble in Water (17 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1. J Albers et al. Mol. Cancer Ther. 2023 22:833 2. F Bladt et al. Clin. Cancer Res. 2013 19:2941 3. M Friese-Hamim et al. Lung Cancer 2022 163:77 4. M Friese-Hamim et al. Am. J. Cancer Res. 2017 7:962 |
| Antibody Specification | |
| Alternate Names | EMD-1214063 |
| Protein Specification | |
| Purity | >98% |
